Adjuvants for Cancer MRNA Vaccines in the Era of Nanotechnology: Strategies, Applications, and Future Directions

Overview

Journal J Nanobiotechnology

Publisher Biomed Central

Specialty Biotechnology

Date 2024 Jun 2

PMID 38825711

Authors

Lei-Ming Cao

Yi-Fu Yu

Zi-Zhan Li

Nian-Nian Zhong

Guang-Rui Wang

Yao Xiao

Bing Liu

Qiu-Ji Wu

Chun Feng

Lin-Lin Bu

Affiliations

Soon will be listed here.

Abstract

Research into mRNA vaccines is advancing rapidly, with proven efficacy against coronavirus disease 2019 and promising therapeutic potential against a variety of solid tumors. Adjuvants, critical components of mRNA vaccines, significantly enhance vaccine effectiveness and are integral to numerous mRNA vaccine formulations. However, the development and selection of adjuvant platforms are still in their nascent stages, and the mechanisms of many adjuvants remain poorly understood. Additionally, the immunostimulatory capabilities of certain novel drug delivery systems (DDS) challenge the traditional definition of adjuvants, suggesting that a revision of this concept is necessary. This review offers a comprehensive exploration of the mechanisms and applications of adjuvants and self-adjuvant DDS. It thoroughly addresses existing issues mentioned above and details three main challenges of immune-related adverse event, unclear mechanisms, and unsatisfactory outcomes in old age group in the design and practical application of cancer mRNA vaccine adjuvants. Ultimately, this review proposes three optimization strategies which consists of exploring the mechanisms of adjuvant, optimizing DDS, and improving route of administration to improve effectiveness and application of adjuvants and self-adjuvant DDS.

Citing Articles

Levamisole, as a viral vaccine adjuvant, induces robust host defense through the modulation of innate and adaptive immune responses.

Kim G, Kwak D, Kim H, Shin S, Ko M, Hwang S Front Microbiol. 2025; 15():1493561.

PMID: 39845058 PMC: 11751227. DOI: 10.3389/fmicb.2024.1493561.

The diverse landscape of RNA modifications in cancer development and progression.

Kim H, Eun J, Jang S, Kim J, Jeong J Genes Genomics. 2024; 47(2):135-155.

PMID: 39643826 DOI: 10.1007/s13258-024-01601-y.

DNA tetrahedron nanoparticles service as a help carrier and adjvant of mRNA vaccine.

Liu H, Li X, Yan R, Yang J, Lu Q, Wang L J Transl Med. 2024; 22(1):1024.

PMID: 39543727 PMC: 11566622. DOI: 10.1186/s12967-024-05837-w.

References

Geijtenbeek T, Gringhuis S . Signalling through C-type lectin receptors: shaping immune responses. Nat Rev Immunol. 2009; 9(7):465-79. PMC: 7097056. DOI: 10.1038/nri2569. View

Cobb M . Who discovered messenger RNA?. Curr Biol. 2015; 25(13):R526-32. DOI: 10.1016/j.cub.2015.05.032. View

Lu T, Hu F, Yue H, Yang T, Ma G . The incorporation of cationic property and immunopotentiator in poly (lactic acid) microparticles promoted the immune response against chronic hepatitis B. J Control Release. 2020; 321:576-588. DOI: 10.1016/j.jconrel.2020.02.039. View

Wang Y, Wu J, Fan Q, Zhou M, Yue Z, Ma G . Novel vaccine delivery system induces robust humoral and cellular immune responses based on multiple mechanisms. Adv Healthc Mater. 2014; 3(5):670-81. DOI: 10.1002/adhm.201300335. View

Li W, Li Y, Li J, Meng J, Jiang Z, Yang C . All-Trans-Retinoic Acid-Adjuvanted mRNA Vaccine Induces Mucosal Anti-Tumor Immune Responses for Treating Colorectal Cancer. Adv Sci (Weinh). 2024; 11(22):e2309770. PMC: 11165559. DOI: 10.1002/advs.202309770. View

Kallen K, Heidenreich R, Schnee M, Petsch B, Schlake T, Thess A . A novel, disruptive vaccination technology: self-adjuvanted RNActive(®) vaccines. Hum Vaccin Immunother. 2013; 9(10):2263-76. PMC: 3906413. DOI: 10.4161/hv.25181. View

Maruggi G, Zhang C, Li J, Ulmer J, Yu D . mRNA as a Transformative Technology for Vaccine Development to Control Infectious Diseases. Mol Ther. 2019; 27(4):757-772. PMC: 6453507. DOI: 10.1016/j.ymthe.2019.01.020. View

Kvarnhammar A, Petterson T, Cardell L . NOD-like receptors and RIG-I-like receptors in human eosinophils: activation by NOD1 and NOD2 agonists. Immunology. 2011; 134(3):314-25. PMC: 3209571. DOI: 10.1111/j.1365-2567.2011.03492.x. View

Swartz M . The physiology of the lymphatic system. Adv Drug Deliv Rev. 2001; 50(1-2):3-20. DOI: 10.1016/s0169-409x(01)00150-8. View

10.

Trinchieri G . Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003; 3(2):133-46. DOI: 10.1038/nri1001. View

11.

Tahtinen S, Tong A, Himmels P, Oh J, Paler-Martinez A, Kim L . IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat Immunol. 2022; 23(4):532-542. DOI: 10.1038/s41590-022-01160-y. View

12.

Da Silva F, Di Pasquale A, Yarzabal J, Garcon N . Safety assessment of adjuvanted vaccines: Methodological considerations. Hum Vaccin Immunother. 2015; 11(7):1814-24. PMC: 4514270. DOI: 10.1080/21645515.2015.1043501. View

13.

Wang Y, Zhang S, Li H, Wang H, Zhang T, Hutchinson M . Small-Molecule Modulators of Toll-like Receptors. Acc Chem Res. 2020; 53(5):1046-1055. DOI: 10.1021/acs.accounts.9b00631. View

14.

Kim J, Eygeris Y, Gupta M, Sahay G . Self-assembled mRNA vaccines. Adv Drug Deliv Rev. 2021; 170:83-112. PMC: 7837307. DOI: 10.1016/j.addr.2020.12.014. View

15.

Shin H, Kang S, Won C, Min D . Enhanced Local Delivery of Engineered IL-2 mRNA by Porous Silica Nanoparticles to Promote Effective Antitumor Immunity. ACS Nano. 2023; 17(17):17554-17567. DOI: 10.1021/acsnano.3c06733. View

16.

Palucka K, Banchereau J . Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12(4):265-77. PMC: 3433802. DOI: 10.1038/nrc3258. View

17.

Qiu M, Tang Y, Chen J, Muriph R, Ye Z, Huang C . Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc Natl Acad Sci U S A. 2022; 119(8). PMC: 8872770. DOI: 10.1073/pnas.2116271119. View

18.

Diamond M, Kinder M, Matsushita H, Mashayekhi M, Dunn G, Archambault J . Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med. 2011; 208(10):1989-2003. PMC: 3182061. DOI: 10.1084/jem.20101158. View

19.

Ndeupen S, Qin Z, Jacobsen S, Bouteau A, Estanbouli H, Igyarto B . The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience. 2021; 24(12):103479. PMC: 8604799. DOI: 10.1016/j.isci.2021.103479. View

20.

Hutchison S, Benson R, Gibson V, Pollock A, Garside P, Brewer J . Antigen depot is not required for alum adjuvanticity. FASEB J. 2011; 26(3):1272-9. PMC: 3289510. DOI: 10.1096/fj.11-184556. View